12.-15. Mai 2014: ESPID, Dublin

Reduced incidence of otitis media among children in Germany after introduction of higher-valent pneumococcal conjugate vaccines

Mathilda Diel1, Maren Laurenz1, Kathrin Krause1, Ralf Sprenger2, Andreas Busse3
1Pfizer Pharma GmbH, Berlin, 2CONVIDIA clinical research GmbH, Münster, 3Kinder- und Jugendarztpraxis, Tegernsee

Link to Poster

Background: Routine infant immunization with the pneumococcal conjugate vaccine PCV7
started in Germany in 2007. In 2009, two higher-valent PCVs were licensed (PCV10 and PCV13)
and replaced PCV7. Aim of this study was to assess the potential impact of PCVs on otitis media
(OM) in children in Germany, especially with regard to the higher-valent vaccines.

Methods: Data from IMS-Health-VIP® were used for uninterrupted time series analyses that
used ICD-10 diagnosis rates as main outcome (H66=suppurative OM, H65=non suppurative OM).
The pre-vaccine period 2003-2006 provided baseline values and was compared to the single
years 2007 to 2012 characterized by a rapidly growing vaccination rate with 7-valent and
higher-valent PCVs in children <2 years of age. Reduction rates (%) were adjusted to the size of
the corresponding age cohorts; the Poisson model was used for statistical analysis.

Results: During the baseline period an average of 1,403,497/391,828 episodes of
suppurative/non-suppurative OM occurred annually in children aged 0-4 years. Subsequently,
episodes for suppurative/non-suppurative OM were found to be reduced significantly (p-value
for all <0.0001): In 2009 by 15.2%/17,5%, and in 2012 by 31.9%/24,2% compared to baseline,
respectively. Analyses among children aged 5-10 years showed similar trends. Within the 6
years from 2007 to 2012, altogether 3,684,330 less episodes of suppurative and nonsuppurative
OM were documented for all children 0-10 years.

Conclusion: A significant reduction in otitis media diagnoses among children in Germany after
implementation of PCV7 was demonstrated. An additional reduction was observed with the
introduction of higher-valent PCVs.

 

 

Reduced incidence of pneumonia among children in Germany after introduction of higher-valent pneumococcal conjugate vaccines

Maren Laurenz1, Ralf Sprenger2, Christof von Eiff1, Andreas Busse3
1Pfizer Pharma GmbH, Berlin, 2CONVIDIA clinical research GmbH, Münster, 3Kinder- und Jugendarztpraxis, Tegernsee

Link to Poster

Background: After implementation of routine infant immunization with pneumococcal
conjugate vaccine PCV7 in Germany in 2007, two higher-valent PCVs were licensed in 2009
(PCV10, PCV13) and replaced PCV7. Aim of this study was to assess the potential impact of PCVs
on pneumonia in children in Germany.

Methods: Data from IMS-Health-VIP® were used for uninterrupted time series analyses using
ICD-10 diagnosis rates as main outcomes (J18=pneumonia; including sub-diagnosis J18.1=lobar
pneumonia, frequently caused by pneumococci). The pre-vaccine period 2003-2006 provided
baseline values and was compared to the single years 2007 to 2012 characterized by rapidly
growing vaccination rates with 7-valent and higher-valent PCVs in children aged <2 years.
Reduction rates (%) were adjusted to the size of the corresponding age cohorts; the Poisson
model was used for statistical analysis.

Results: Episodes of pneumonia initially (in 2008) decreased in children aged 0-4 years and reincreased
until 2011. In 2012, a significant reduction of 22.8% (p<0.0001) compared to baseline
was observed. Of particular interest, episodes of lobar pneumonia decreased by 87.6% in 2008.
Until 2011, a temporarily increase was also observed for episodes of lobar pneumonia, followed
by a re-decrease in 2012 with a significant reduction of 55.5% (p<0.0001) compared to baseline.
Analysis among children aged 5-10 years showed similar trends. Within the six years from 2007
to 2012, altogether 447.476 less episodes of pneumonia were documented for all children 0-10
years.

Conclusion: After introduction of higher-valent PCVs a consolidated and significant reduction in
pneumonia diagnoses among children in Germany was demonstrated.